NCT00275431View on ClinicalTrials.gov

Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Follicular LymphomaDiffuse Large Cell LymphomaMantle Cell LymphomaSmall Lymphocytic LymphomaChronic Lymphocytic Leukemia
Interventions
DRUG

AT-101

Oral

Trial Locations (11)

Unknown

Birmingham

San Diego

Atlanta

Chicago

Boston

New York

Rochester

High Point

Hilton Head Island

Memphis

Burlington

Sponsors
All Listed Sponsors
lead

Ascenta Therapeutics

INDUSTRY

NCT00275431 - Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies | Biotech Hunter | Biotech Hunter